FDA Inspection 1162967 — Diamond Institute For Infertility And Menopause

Diamond Institute For Infertility And Menopause — FEI 3003945103

The FDA completed an inspection of Diamond Institute For Infertility And Menopause on Feb 23, 2022 in Millburn, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). 5 citations were issued during this inspection. Product area: Biologics.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Feb 23, 2022
Fiscal Year
2022
Product Type
Biologics
Project Area
Vaccines and Allergenic Products
Location
Millburn, NJ (United States)

Citations

IDCFRDescription
1221321 CFR 1271.47(a)Testing, screening, donor eligibility procedures
1223921 CFR 1271.55(b)(2)Listing and interpretation of CD tests performed
1225521 CFR 1271.60(c)Shipped but not kept in quarantine
1227721 CFR 1271.75(a)(1)Risk factors, clinical evidence
1229021 CFR 1271.80(d)(1)Reactive tests--not determined ineligible

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.